US › Healthcare

Cibus Global LLC (CBUS)

US · Healthcare · Biotechnology

$1.63+7.95%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$994,000

Revenue YoY

+6.5%

Net profit

$-22.1M

EPS

$-0.29

EPS estimate

$-0.26

Net margin

-2,227.9%

EPS came in at -0.29 against a street estimate of -0.26 — a miss of 11.5%.

Key statistics

Market cap

$120.8M

Forward P/E

0.0

P/B

7.69

Book value

$0.19

EPS (TTM)

$-1.59

52-week high

$4.19

52-week low

$1.09

50-day MA

$1.77

200-day MA

$1.88

Beta

1.59

Analyst view

Analysts rate Cibus Global LLC a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $14.33.

Shareholding

Insiders

26.10%

Institutions

29.16%

Largest institutional holders

Fund	Stake
FMR Inc	14.95%
Vanguard Capital Management, LLC	2.77%
Davidson Kempner Capital Management LP	2.00%
Weiss Asset Management LP	1.16%
United Capital Financial Advisers Inc	0.75%
Geode Capital Management, LLC	0.63%
BlackRock Inc	0.54%
Prescott Group Capital Management LLC	0.43%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cibus Global LLC — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.